Educational needs of primary care physicians regarding direct-to-consumer genetic testing
Karen P Powell1, Carol A Christianson, Whitney A Cogswell
1Center for Biotechnology, Genomics & Health Research, The University of North Carolina at Greensboro, Greensboro, NC 27402-6170, USA. klpowel2@uncg.edu
Journal of Genetic Counseling
|December 31, 2011
Summary
Primary care physicians (PCPs) need more education on direct-to-consumer (DTC) genetic testing. Most PCPs feel unprepared to discuss DTC genetic testing with patients, highlighting a significant educational gap.
Area of Science:
- Medical Education
- Genetics
- Primary Care
Background:
- Direct-to-consumer (DTC) genetic testing is increasingly accessible to patients.
- Primary care physicians (PCPs) are often the first point of contact for patient inquiries about genetic testing.
- There is a need to understand PCPs' current knowledge and educational requirements regarding DTC genetic testing.
Purpose of the Study:
- To evaluate the educational needs of North Carolina PCPs concerning DTC genetic testing.
- To identify PCPs' awareness levels and perceived clinical utility of DTC genetic testing.
- To determine factors influencing PCPs' desire for further education on DTC genetic testing.
Main Methods:
- A survey was distributed to 2,402 family and internal medicine providers in North Carolina.
- The survey assessed PCPs' preparedness, awareness, and interest in DTC genetic testing.
- Statistical analysis, including odds ratios, was used to identify factors associated with wanting to learn more.
Main Results:
- 85% of responding PCPs felt unprepared to answer patient questions about DTC genetic testing.
- 74% of PCPs expressed a desire for more education on DTC genetic testing.
- Only 39% of PCPs were aware of DTC genetic testing, and 43% of those aware found it clinically useful.
Conclusions:
- North Carolina PCPs demonstrate a significant need for education on DTC genetic testing.
- PCPs' lack of awareness and preparedness hinders their ability to guide patients regarding DTC genetic testing.
- Educational programs should utilize familiar and trusted channels to equip PCPs with necessary information and tools.
Related Concept Videos
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...